Interview
Race to Save Humanity: Inside $12B Colossal Biosciences & $3.8B Astromech
- Forecasts indicate a potential loss of up to 50% of global biodiversity within the next 25 years.
- The team aims to generate the next birth of an extinct species within 12 months and successfully completed a woolly mouse experiment to revive the woolly mammoth.
- Capital raising is expected to exceed previous targets following an oversubscribed round that reached $400 million against a $200 million goal.
- A new spin-out entity named Astromech will be launched to utilize AI for focused drug discovery models.
- Plans include deploying a "digital twin of nature" using AI, potentially augmented by quantum computing, to enable real-time analysis of human impacts on water purity, food security, and zoonotic diseases.
- The company intends to automate embryology and cloning processes using robotics and implement enterprise AI systems to aggregate operational data from spreadsheets, JIRA, and smart sheets.
- A vertical integration strategy will cover the entire supply chain from animal operations to ancient DNA extraction.
- Technology development focuses on exceeding current capabilities by performing hundreds of simultaneous genome edits via new constructs, compared to a previous five-to-seven edit benchmark.
- Product goals include a 5X increase in ethically harvested fabric grown from elephant stem cells and the productionization of a critically endangered bird for Middle Eastern falconian culture using artificial eggs.
- Operational targets involve eradicating the screw worm problem within six to seven months, potentially saving taxpayers billions over a decade.
- Strategic plans encompass returning extinct species, gene drives, and cloned endangered animals to the wild with government and indigenous support, alongside educating the USDA, intelligence community, and Department of War on gene drive applications.
- The company intends to open-source conservation technologies for public use while retaining the right to enforce conservation-only usage and provide legal feedback for nefarious applications.
- The firm plans to build a global distributed bio vault network and expand a global network for endangered species production and biobanking.
- A real-time camera feed displaying dire wolves is planned for the lobby once the high-definition camera system is fully operational.
- The business model explicitly excludes the sale of animals, megalodons, humans, non-human primates, or Gigantopithecus, despite receiving related requests.
- De-extinction is positioned as a complementary toolkit for modern conservation rather than a replacement for it.
- The company anticipates a "pre-Cambrian explosion" of new drugs and therapies driven by the convergence of AI and biotech.
- Long-term predictions suggest the ability to program life, such as growing trees into houses, through the intersection of AI, quantum computing, and synthetic biology.
- Internal focus remains on reprogramming scientists to operate within software-like systems while maintaining inspiration alongside value creation for investors.
- Unique science streetwear will remain exclusive to employees and favorite guests rather than being sold to the public.
- Ben Lamb warns that "bad actors" may misuse open-sourced technologies, requiring vigilance regarding their deployment.